Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abraxis BioScience is set to present results from a dose escalation trial of infusion of Abraxane directly into the bladder in the patients who failed standard chemotherapy will be presented at the 2010 American Urological Association Annual Meeting in San Francisco.
Subscribe to our email newsletter
Findings from Abraxis BioScience phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab(R)) driven chemotherapy, nab-paclitaxel (Abraxane for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
James McKiernan, director of urologic oncology, department of urology, Herbert Irving Comprehensive Cancer Center, Columbia University, said: “The preliminary results of this study suggest nab-paclitaxel may have a potential benefit for high-risk non-muscle-invasive bladder cancer patients who have failed prior intravesical treatment or who are unable or unwilling to undergo cystectomy.”
Patrick Soon-Shiong, executive chairman and founder of Abraxis BioScience, said: “The promising results of Abraxane in the treatment of patients with bladder cancer support the efficacy of nab-driven chemotherapy across an increasing range of advanced and difficult-to-treat cancers.
“This study further supports our commitment to develop a deeper understanding of how albumin-bound Abraxane’s unique affinity for the secreted protein Sparc may enable targeted cytoxotic agents to be delivered directly into the tumor microenvironment, supporting better patient outcomes.”